earnings
confidence high
sentiment positive
materiality 0.80
Veracyte Q3 revenue up 14% to $131.9M, raises FY guidance; adjusted EBITDA margin 30%
VERACYTE, INC.
2025-Q3 EPS reported
$0.32
revenue$376,509,000
- Total revenue $131.9M (+14% YoY); testing rev $127.8M (+17%); GAAP net income $19.1M.
- Decipher revenue $82.2M (+26%); Afirma $43.2M (+7%); total testing volume +19% to 43,679.
- Adjusted EBITDA $39.7M (30% margin); cash from ops $44.8M; cash & equivalents $366.4M.
- Raised FY2025 total revenue guidance to $506-510M; testing rev guidance $484-487M (+16%).
- Completed enrollment of Percepta Nasal Swab NIGHTINGALE trial; upcoming TrueMRD and Prosigna LDT launches.